Consuelo Marín-Vicente
Consuelo Marín-Vicente has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Cristina Villa del Campo
Genetic Control of Development and Organ Regeneration Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
3 shared publicationsEnrique Calvo
Proteomics Unit, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
3 shared publications- Jesús Vázquez
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
3 shared publications - Miguel Torres
Affiliations Cardiovascular Regeneration Program, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
3 shared publications Rocío Sierra
Genetic Control of Development and Organ Regeneration Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
3 shared publicationsRoman A. Zubarev
Division of Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
3 shared publications
Latest Publications
- Open Access
- 22 May 2026
- Published by Springer Nature in Genome Biology
- Vol. 27 (1)
Pro-regenerative fingerprints identified in a sub-population of adult mouse cardiomyocytes by integrative single-cell proteomics
Recent advances in instrument sensitivity and sample preparation techniques are significantly improving the ability to study the heterogeneity of cell popu
- 22 May 2026
- Published by Springer Nature in Genome Biology
- Vol. 27 (1)
Open AccessPro-regenerative fingerprints identified in a sub-population of adult mouse cardiomyocytes by integrative single-cell proteomics
Recent advances in instrument sensitivity and sample preparation techniques are significantly improving the ability to study the heterogeneity of cell popu
- Open Access
- 4 September 2024
- Published by Springer Nature
- Vol. 2817, C1
Correction to: A Sample Preparation Procedure for Isobaric Labeling-Based Single-Cell Proteomics
- 4 September 2024
- Published by Springer Nature
- Vol. 2817, C1
Open AccessCorrection to: A Sample Preparation Procedure for Isobaric Labeling-Based Single-Cell Proteomics
- 22 June 2024
- Published by Springer Nature
- Vol. 2817, 33-43
A Sample Preparation Procedure for Isobaric Labeling-Based Single-Cell Proteomics
Mass spectrometry-based proteomics has traditionally been limited by the amount of input material for analysis. Single-cell proteomics has emerged as a challenging discipline due to the ultra-high sensitivity required. Isobaric labeling-based multiplex strategies with a carrier proteome offer an approach to overcome the sensitivity limitations. Following this as the basic strategy, we show here the general workflow for preparing cells for single-cell mass spectrometry-based proteomics. This protocol can also be applied to manually isolated cells when large cells, such as cardiomyocytes, are difficult to isolate properly with conventional fluorescence-activated cell sorting (FACS) sorter methods.
- 22 June 2024
- Published by Springer Nature
- Vol. 2817, 33-43
A Sample Preparation Procedure for Isobaric Labeling-Based Single-Cell Proteomics
Mass spectrometry-based proteomics has traditionally been limited by the amount of input material for analysis. Single-cell proteomics has emerged as a challenging discipline due to the ultra-high sensitivity required. Isobaric labeling-based multiplex strategies with a carrier proteome offer an approach to overcome the sensitivity limitations. Following this as the basic strategy, we show here the general workflow for preparing cells for single-cell mass spectrometry-based proteomics. This protocol can also be applied to manually isolated cells when large cells, such as cardiomyocytes, are difficult to isolate properly with conventional fluorescence-activated cell sorting (FACS) sorter methods.
- Open Access
- 14 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 14023
Deciphering the Role and Signaling Pathways of PKCα in Luminal A Breast Cancer Cells
Protein kinase C (PKC) comprises a family of highly related serine/threonine protein kinases involved in multiple signaling pathways, which control cell proliferation, survival, and differentiation. The role of PKCα in cancer has been studied for many years. However, it has been impossible to establish whether PKCα acts as an oncogene or a tumor suppressor. Here, we analyzed the importance of PKCα in cellular processes such as proliferation, migration, or apoptosis by inhibiting its gene expression in a luminal A breast cancer cell line (MCF-7). Differential expression analysis and phospho-kinase arrays of PKCα-KD vs. PKCα-WT MCF-7 cells identified an essential set of proteins and oncogenic kinases of the JAK/STAT and PI3K/AKT pathways that were down-regulated, whereas IGF1R, ERK1/2, and p53 were up-regulated. In addition, unexpected genes related to the interferon pathway appeared down-regulated, while PLC, ERBB4, or PDGFA displayed up-regulated. The integration of this information clearly showed us the usefulness of inhibiting a multifunctional kinase-like PKCα in the first step to control the tumor phenotype. Then allowing us to design a possible selection of specific inhibitors for the unexpected up-regulated pathways to further provide a second step of treatment to inhibit the proliferation and migration of MCF-7 cells. The results of this study suggest that PKCα plays an oncogenic role in this type of breast cancer model. In addition, it reveals the signaling mode of PKCα at both gene expression and kinase activation. In this way, a wide range of proteins can implement a new strategy to fine-tune the control of crucial functions in these cells and pave the way for designing targeted cancer therapies.
- 14 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 14023
Open AccessDeciphering the Role and Signaling Pathways of PKCα in Luminal A Breast Cancer Cells
Protein kinase C (PKC) comprises a family of highly related serine/threonine protein kinases involved in multiple signaling pathways, which control cell proliferation, survival, and differentiation. The role of PKCα in cancer has been studied for many years. However, it has been impossible to establish whether PKCα acts as an oncogene or a tumor suppressor. Here, we analyzed the importance of PKCα in cellular processes such as proliferation, migration, or apoptosis by inhibiting its gene expression in a luminal A breast cancer cell line (MCF-7). Differential expression analysis and phospho-kinase arrays of PKCα-KD vs. PKCα-WT MCF-7 cells identified an essential set of proteins and oncogenic kinases of the JAK/STAT and PI3K/AKT pathways that were down-regulated, whereas IGF1R, ERK1/2, and p53 were up-regulated. In addition, unexpected genes related to the interferon pathway appeared down-regulated, while PLC, ERBB4, or PDGFA displayed up-regulated. The integration of this information clearly showed us the usefulness of inhibiting a multifunctional kinase-like PKCα in the first step to control the tumor phenotype. Then allowing us to design a possible selection of specific inhibitors for the unexpected up-regulated pathways to further provide a second step of treatment to inhibit the proliferation and migration of MCF-7 cells. The results of this study suggest that PKCα plays an oncogenic role in this type of breast cancer model. In addition, it reveals the signaling mode of PKCα at both gene expression and kinase activation. In this way, a wide range of proteins can implement a new strategy to fine-tune the control of crucial functions in these cells and pave the way for designing targeted cancer therapies.